1. Home
  2. NBTX vs CTW Comparison

NBTX vs CTW Comparison

Compare NBTX & CTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBTX
  • CTW
  • Stock Information
  • Founded
  • NBTX 2003
  • CTW 2013
  • Country
  • NBTX France
  • CTW Japan
  • Employees
  • NBTX N/A
  • CTW N/A
  • Industry
  • NBTX Biotechnology: Pharmaceutical Preparations
  • CTW EDP Services
  • Sector
  • NBTX Health Care
  • CTW Technology
  • Exchange
  • NBTX Nasdaq
  • CTW Nasdaq
  • Market Cap
  • NBTX 211.9M
  • CTW 171.4M
  • IPO Year
  • NBTX 2020
  • CTW 2025
  • Fundamental
  • Price
  • NBTX $9.85
  • CTW $2.17
  • Analyst Decision
  • NBTX Strong Buy
  • CTW
  • Analyst Count
  • NBTX 1
  • CTW 0
  • Target Price
  • NBTX $8.00
  • CTW N/A
  • AVG Volume (30 Days)
  • NBTX 15.0K
  • CTW 457.5K
  • Earning Date
  • NBTX 09-17-2025
  • CTW 01-01-0001
  • Dividend Yield
  • NBTX N/A
  • CTW N/A
  • EPS Growth
  • NBTX N/A
  • CTW N/A
  • EPS
  • NBTX N/A
  • CTW N/A
  • Revenue
  • NBTX N/A
  • CTW $76,194,020.00
  • Revenue This Year
  • NBTX N/A
  • CTW N/A
  • Revenue Next Year
  • NBTX $74.67
  • CTW N/A
  • P/E Ratio
  • NBTX N/A
  • CTW $47.42
  • Revenue Growth
  • NBTX N/A
  • CTW 8.71
  • 52 Week Low
  • NBTX $2.76
  • CTW $1.71
  • 52 Week High
  • NBTX $10.59
  • CTW $4.88
  • Technical
  • Relative Strength Index (RSI)
  • NBTX 75.73
  • CTW N/A
  • Support Level
  • NBTX $8.20
  • CTW N/A
  • Resistance Level
  • NBTX $10.59
  • CTW N/A
  • Average True Range (ATR)
  • NBTX 0.51
  • CTW 0.00
  • MACD
  • NBTX 0.18
  • CTW 0.00
  • Stochastic Oscillator
  • NBTX 79.95
  • CTW 0.00

About NBTX Nanobiotix S.A.

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Share on Social Networks: